Advanced Search
MyIDEAS: Login to save this paper or follow this series

Implementing the continual reassessment method (CRM)

Contents:

Author Info

  • Adrian Mander

    (MRC Biostatistics Unit Hub for Trials Methodology, Cambridge)

Abstract

One of the aims of a phase I trial in oncology is to find the maximum tolerated dose. A set of doses is administered to participants starting from the lowest dose in increasing steps. To do this safely, the toxicity of each dose is assessed, and a decision is made about whether to proceed with the next highest dose until the desired target toxicity level is found. A suitable dose is then chosen to take forward into phase II studies to discover whether this drug is efficacious. The majority of oncology phase I trials use algorithm-based rules such as the 3 + 3 design to escalate doses; the 3 + 3 design is easy to implement by nonstatisticians but is statistically inefficient. Other designs, such as the continual reassessment method (O'Quigley, Pepe, and Fisher 1990), use a model to help guide the decision of which dose to give. The complexity of the CRM and that it requires software may be reasons why it is not more widely used. This talk will describe a new command crm that is a Mata implementation of the CRM and includes some discussion about the programming difficulties.

Download Info

If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
File URL: http://repec.org/usug2011/UK11_Mander.pdf
File Function: presentation slides
Download Restriction: no

Bibliographic Info

Paper provided by Stata Users Group in its series United Kingdom Stata Users' Group Meetings 2011 with number 04.

as in new window
Length:
Date of creation: 26 Sep 2011
Date of revision:
Handle: RePEc:boc:usug11:04

Contact details of provider:
Web page: http://www.stata.com/meeting/uk11
More information through EDIRC

Related research

Keywords:

This paper has been announced in the following NEP Reports:

References

No references listed on IDEAS
You can help add them by filling out this form.

Citations

Lists

This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.

Statistics

Access and download statistics

Corrections

When requesting a correction, please mention this item's handle: RePEc:boc:usug11:04. See general information about how to correct material in RePEc.

For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Christopher F Baum).

If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

If references are entirely missing, you can add them using this form.

If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.

If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.

Please note that corrections may take a couple of weeks to filter through the various RePEc services.